Overview

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
0
Participant gender:
All
Summary
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time, the occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Collaborator:
Janssen Research & Development, LLC
Treatments:
Platelet Aggregation Inhibitors
Rivaroxaban
Warfarin
Criteria
Inclusion Criteria:

- All male and female patients who have been prescribed for the first time either
Rivaroxaban or standard of care from the date of market authorization of rivaroxaban
to Dec 31, 2017

Exclusion Criteria:

- Patients who have any record of being prescribed their index drug prior to the enrolment
period or who qualify as members of both cohorts on the same day, will be excluded